Wegovy and the Medicare GLP-1 Bridge

Wegovy is covered under the Bridge in both forms — the familiar injection and the tablets — when prescribed for weight reduction and maintenance. If you've been paying $400+ a month through NovoCare, this program was built with you in mind.

Already paying cash for Wegovy? Read this first.

Two pieces of good news. First, self-pay use doesn't disqualify you — only receiving a GLP-1 through your Part D plan routes a request away from the Bridge. Second, the program assesses BMI at the time you started therapy, not today. If Wegovy has already helped you lose weight, your starting BMI is the one that counts toward the criteria. Find your starting weight before the visit — old chart notes or your NovoCare history can help.

What you'll pay

Through the Bridge, Wegovy costs $50 for a one-month supply — the same copay as the Zepbound KwikPen or Foundayo. Per CMS, that $50 doesn't count toward your Part D deductible or the annual $2,100 out-of-pocket cap, so it stays outside your normal Part D spending. For someone paying $400 or more a month through NovoCare today, that's the entire reason the Bridge exists. (Source: CMS.)

Injection or tablets — and the oral alternative

Because both the Wegovy injection and the Wegovy oral tablets are covered, you and your doctor can pick the form that fits your life. If a weekly injection has been the sticking point, say so — there's also Foundayo (orforglipron), a once-daily oral GLP-1 covered under the same $50 Bridge copay. None of these choices changes your eligibility; they're about preference and what your clinician thinks is appropriate.

A higher-dose option: Wegovy HD

As of March 2026 there's a higher-dose Wegovy injection — Wegovy HD (semaglutide 7.2 mg) — which produced about 20.7% average weight loss in its trial (STEP UP), the most for a Wegovy injection so far and close to tirzepatide's level. Because the Bridge covers all Wegovy dose strengths, it's included for the same $50 copay for those who qualify. Side effects resemble the standard dose: gastrointestinal effects were modestly more common at 7.2 mg than 2.4 mg (about 71% vs 61%), with a low rate of stopping because of them (3.3% vs 2.0%). One more thing to raise with your clinician: at the higher dose, altered skin sensation (dysesthesia) was reported more often than at the standard 2.4 mg dose. Whether the higher dose is right for you is a clinical decision.

Curious how they stack up? See weight loss and side effects compared across Wegovy, Zepbound, and Foundayo, with the trial numbers.

One Wegovy wrinkle: the heart-protection indication

Wegovy is also approved to reduce cardiovascular risk in people with established heart disease. That's a different indication — and because the Bridge is specifically for weight management, a prescription written for cardiovascular risk reduction would go through your regular Part D plan instead. If you have established cardiovascular disease and your doctor might prescribe Wegovy partly for that reason, flag it; your clinician decides which path applies. The Bridge vs. Part D guide covers this in depth.

What to bring your doctor

• Current height, weight, and your weight when you started Wegovy (if applicable)
• How you've paid for it so far — "I buy it through NovoCare" is a useful sentence
• Diagnosed conditions relevant to the criteria pathways
• Your experience so far: dose, side effects, results
• Your Medicare drug plan card

How to ask

Keep it simple: "Could we discuss whether Wegovy is medically appropriate for me, and whether my situation fits the new Medicare GLP-1 Bridge?" The free screener writes a fuller version with your numbers filled in, and the doctor packet includes the prescribing steps your clinician will need for this brand-new program.

Sources and review status: Content reviewed June 27, 2026, based on published CMS materials including the prescriber fact sheet (CMS Product No. 12235). Check current CMS materials: CMS Bridge overview, beneficiary fact sheet (PDF), provider information.